Alternative redox forms of ASNA-1 separate insulin signaling from tail-anchored protein targeting and cisplatin resistance in C. elegans

Cisplatin is a frontline cancer therapeutic, but intrinsic or acquired resistance is common. We previously showed that cisplatin sensitivity can be achieved by inactivation of ASNA-1/TRC40 in mammalian cancer cells and in Caenorhabditis elegans. ASNA-1 has two more conserved functions: in promoting...

Descripción completa

Detalles Bibliográficos
Autores principales: Raj, Dorota, Billing, Ola, Podraza-Farhanieh, Agnieszka, Kraish, Bashar, Hemmingsson, Oskar, Kao, Gautam, Naredi, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060345/
https://www.ncbi.nlm.nih.gov/pubmed/33883621
http://dx.doi.org/10.1038/s41598-021-88085-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060345/
https://www.ncbi.nlm.nih.gov/pubmed/33883621
http://dx.doi.org/10.1038/s41598-021-88085-y

Ejemplares similares